RVO

Par Pacific Reports Fourth Quarter and Record 2023 Results

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Par Pacific Holdings, Logistics, News, Table, Adjustment, RVO, GAAP, Webcast, Public expenditure, Central Time, Par, Video game

HOUSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the fourth quarter and twelve months ended December 31, 2023.

Key Points: 
  • HOUSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the fourth quarter and twelve months ended December 31, 2023.
  • Fourth quarter 2023 Adjusted Net Income was $65.2 million, compared to $132.8 million in the fourth quarter of 2022.
  • Fourth quarter 2023 Adjusted EBITDA was $122.0 million, compared to $174.9 million in the fourth quarter of 2022.
  • Refining segment Adjusted EBITDA was $106.5 million in the fourth quarter of 2023, compared to $146.4 million in the fourth quarter of 2022.

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Paratriathlon, Inflammation, Ranibizumab, Research, Ophthalmology, RVO, Patient, Diabetic retinopathy, Swelling, CRVO, BRVO, Food, ROG, Bascom Palmer Eye Institute, Retina, Blood, Macular edema, Angiogenesis, Roche, Eye, CST, Telescopic sight

In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.

Key Points: 
  • In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.
  • Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.
  • In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.
  • “The sustained vision improvements and retinal drying seen up to 72 weeks reaffirm Vabysmo as an effective treatment for retinal vein occlusion,” said Ramin Tadayoni, M.D., Ph.D., head of ophthalmology at Université Paris Cité in Paris and president of EURETINA, who is presenting the data at Angiogenesis.

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

Retrieved on: 
Monday, January 29, 2024
Patient, Head, Knowledge, Partnership, Geographic atrophy, AMD, Diabetic retinopathy, Ranibizumab, MPH, RVO, DME, Pharmaceutical industry

Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company.

Key Points: 
  • Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company.
  • In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to $248 million, plus single digit royalties on global net sales of commercialized products, if any.
  • Eyconis will initially be based in Redwood City, California, and certain employees of Ascendis are expected to join the newly formed company.
  • Eyconis is led by ophthalmology industry veteran, Emmett Cunningham, M.D., Ph.D., MPH, Senior Partner at HealthQuest Capital, who joins Eyconis as Executive Chairman, and experienced biopharmaceutical executive Oliver Boris Stauch, who joins Eyconis as Chief Operating Officer after serving previously as Head of Ophthalmology at Ascendis Pharma.

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Floater, Cataract, Marketing, Protein, BRVO, INN, Neovascularization, Complication, ATC, DME, Endophthalmitis, Retinal detachment, Blood, Bleeding, International, Ranibizumab, AMD, Injection, Disease, Diabetes, Language, CRVO, Eye, Pressure, Swelling, Inflammation, Intraocular pressure, RVO, European Medicines Agency, Infection, Cerebral edema, CNV, Growth, Select, Macular edema, Patient, Safety, Anatomy, Paratriathlon, Retina, IIA, Retinal haemorrhage, Three-body problem, Medical device

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Vertex Energy Meets Renewable Fuel Standard Revised Annual Compliance Report Filing Deadline of December 1, 2023, for Calendar Year 2022

Retrieved on: 
Tuesday, December 5, 2023
Other Energy, Environment, Technology, Oil, Gas, Other Technology, Alternative Energy, Energy, EPA, RFS, RVO, Gasoline, Mobile

The EPA previously extended obligated parties’ RFS compliance and attestation engagement reporting deadlines for CY 2022 from March 31, 2023, to December 1, 2023.

Key Points: 
  • The EPA previously extended obligated parties’ RFS compliance and attestation engagement reporting deadlines for CY 2022 from March 31, 2023, to December 1, 2023.
  • Due to the off-cycle nature of this event, the Company is providing this update on its RFS compliance efforts with respect to the Mobile Refinery’s production of conventional gasoline and diesel fuel.
  • The Company reports that the Mobile Refinery has satisfied its RVO for CY 2022, and that Vertex Refining Alabama LLC now has the option to elect to carry its CY 2023 RVO to CY 2024.
  • The anticipated deadline for the filing of the RFS annual compliance report for CY 2024 is March 31, 2025.

Par Pacific Holdings Reports Third Quarter 2023 Results

Retrieved on: 
Monday, November 6, 2023
Par Pacific Holdings, NYSE, Public expenditure, Par, Billings, Montana, News, GAAP, Acquisition, RVO, Webcast, Central Time, ABL, Table, Logistics, Rare-earth element, Video game, Beauty salon, Naval stores industry, Compact Disc manufacturing, Cryptocurrency, Retail

HOUSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the quarter ended September 30, 2023.

Key Points: 
  • HOUSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the quarter ended September 30, 2023.
  • Third quarter 2023 Adjusted Net Income was $193.5 million, compared to $172.0 million in the third quarter of 2022.
  • Third quarter 2023 Adjusted EBITDA was $255.7 million, compared to $214.1 million in the third quarter of 2022.
  • Refining segment Adjusted EBITDA was $233.6 million in the third quarter of 2023, compared to $187.8 million in the third quarter of 2022.

mPulse Recognizes Innovative Healthcare Organizations in the Sixth Annual Activate 2023 Awards

Retrieved on: 
Tuesday, October 31, 2023
Data Management, Medical Supplies, Technology, General Health, Telemedicine, Virtual Medicine, Mobile, Wireless, Apps, Applications, Consumer, Pharmaceutical, Mental Health, Medical Devices, Baby, Maternity, Health Technology, Hospitals, Dental, Other Technology, Artificial Intelligence, Software, Health, Internet, Knowledge, SMS, Education, OB, PHI, Emergency department, Blood pressure, SME, Habit, UnitedHealth Group, MEDLINE, Digital technology, L.A, RVO, Diabetes, Mother, COVID, Health equity, Red Ventures, National Health Planning and Resources Development Act, Medicaid, AI, Patient, L.A. Care Health Plan, Activate, Urban Health Resource Centre, Pharmaceutical industry, Nursing, Health insurance, Mobile phone, Latinx

mPulse , the leader in conversational AI and digital engagement solutions for the healthcare industry, announced the winners of the Activate 2023 Awards.

Key Points: 
  • mPulse , the leader in conversational AI and digital engagement solutions for the healthcare industry, announced the winners of the Activate 2023 Awards.
  • The awards recognize key customers and healthcare organizations who showcase industry-leading health outcomes, technology innovation, and health equity results for members.
  • The winners were announced at mPulse’s annual Activate conference where industry leaders and SMEs share innovative strategies for digital health activation to over 200 participants across the healthcare ecosystem.
  • Activate Award participants include healthcare industry leaders and innovative health plans focused on improving patient outcomes, incorporating behavioral science into member journey design, and addressing other critical engagement goals.

Healthline Awards Maternal Health Grant to National Birth Justice Organization Ancient Song

Retrieved on: 
Tuesday, October 31, 2023
Human, Health equity, Health, Alaska Natives, Mortality, Conference, Disease, Healthline, Infant, Social support, RVO, White, Pregnancy, Partnership, Doula, Social impact, African Americans, Woman, Birth control

NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Healthline Media, the leading digital health and wellness property, today announced a collaboration with Ancient Song, a national birth justice organization working to eliminate maternal and infant mortality and morbidity among low-income Black and Latinx people. The partnership underscores Healthline Media's dedication to improving access to care for all birthing people, especially given that African American, American Indian and Alaskan Native, and Latinx Women are more likely to experience negative outcomes in comparison to White women before, during and after pregnancy.

Key Points: 
  • NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Healthline Media, the leading digital health and wellness property, today announced a collaboration with Ancient Song, a national birth justice organization working to eliminate maternal and infant mortality and morbidity among low-income Black and Latinx people.
  • We are excited to support Ancient Song as they expand their postpartum services and continue the very important work of birth justice advocacy."
  • "Ancient Song is excited about this opportunity to partner with Healthline and RVO Health to push health equity in New York City," said Chanel Porcia-Albert, founder and chief executive director at Ancient Song.
  • Learn more about the programming here and about Healthline Media's health equity and social impact work in the maternal health space here .

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

Retrieved on: 
Friday, October 27, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, ROG, Food, Ranibizumab, RO, AMD, DME, Injection, Warning, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Retinal vasculitis, RVO, Diabetic retinopathy, Colic flexures, Paratriathlon, Vascular occlusion, Roche, Eye, Macular edema, Neovascularization, Pharmaceutical industry, Vaccine, Faricimab, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).
  • RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
  • Together, the three retinal conditions affect around 3 million people in the U.S. and are among the leading causes of vision loss.
  • This was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluid.

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Retrieved on: 
Tuesday, October 10, 2023
Research, FDA, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Optical, Science, Retina, Paratriathlon, European, HIV disease progression rates, RVO, Angiogenesis, Food, Neovascularization, Inflammation, DME, United Kingdom, Roche, ROG, CRVO, BRVO, AMD, Blood, Phase, RO, Faricimab, Diabetic retinopathy, Maintenance, Macular edema, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Medicines Agency, Pharmaceutical industry, Medical imaging, Vaccine, Genentech

Data showed people treated with Vabysmo extended their treatment intervals up to every four months while maintaining the vision gains achieved in the first 24 weeks of the trials.

Key Points: 
  • Data showed people treated with Vabysmo extended their treatment intervals up to every four months while maintaining the vision gains achieved in the first 24 weeks of the trials.
  • Vabysmo continued to show robust and sustained drying of retinal fluid from baseline up to week 72, as measured by reduction in central subfield thickness.
  • This is the first time that vision and anatomical improvements have been maintained for more than a year using a personalized treat-and-extend dosing regimen in both global Phase III BRVO and CRVO trials.
  • In both studies, Vabysmo was generally well-tolerated and the safety profile was consistent with previous trials.